Please use this identifier to cite or link to this item:
Title: Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
Author: Garcia Carbonero, Rocio
Bazan Peregrino, Miriam
Gil Martin, Marta
Álvarez, Rafael
Macarulla, Teresa
Riesco Martinez, Maria C.
Verdaguer, Helena
Guillén Ponce, Carmen
Farrera Sal, Martí
Moreno, Rafael
Mato Berciano, Ana
Maliandi, Maria Victoria
Torres Manjon, Silvia
Costa, Marcel
Pozo, Natalia del
Martínez de Villarreal, Jaime
Real, Francisco X.
Vidal, Noemí
Capella, Gabriel
Alemany Bonastre, Ramon
Blasi, Emma
Blasco, Carmen
Cascallò, Manel
Salazar Soler, Ramón
Keywords: Càncer
Issue Date: 1-Mar-2022
Publisher: BMJ
Abstract: Background VCN-01 is an oncolytic adenovirus (Ad5 based) designed to replicate in cancer cells with dysfunctional RB1 pathway, express hyaluronidase to enhance virus intratumoral spread and facilitate chemotherapy and immune cells extravasation into the tumor. This phase I clinical trial was aimed to find the maximum tolerated dose/recommended phase II dose (RP2D) and dose-limiting toxicity (DLT) of the intravenous delivery of the replication-competent VCN-01 adenovirus in patients with advanced cancer. Methods Part I: patients with advanced refractory solid tumors received one single dose of VCN-01. Parts II and III: patients with pancreatic adenocarcinoma received VCN-01 (only in cycle 1) and nab-paclitaxel plus gemcitabine (VCN-concurrent on day 1 in Part II, and 7days before chemotherapy in Part III). Patients were required to have anti-Ad5 neutralizing antibody (NAbs) titers lower than 1/350 dilution. Pharmacokinetic and pharmacodynamic analyses were performed. Results 26% of the patients initially screened were excluded based on high NAbs levels. Sixteen and 12 patients were enrolled in Part I and II, respectively: RP2D were 1 x10(13) viral particles (vp)/patient (Part I), and 3.3x10(12) vp/patient (Part II). Fourteen patients were included in Part Ill: there were no DLTs and the RP2D was 1 x10(13) vp/patient. Observed DLTs were grade 4 aspartate aminotransferase increase in one patient (Part I, 1x10(13) vp), grade 4 febrile neutropenia in one patient and grade 5 thrombocytopenia plus enterocolitis in another patient (Part II, 1 x10(13) vp). In patients with pancreatic adenocarcinoma overall response rate were 50% (Part II) and 50% (Part III). VCN-01 viral genomes were detected in tumor tissue in five out of six biopsies (day 8). A second viral plasmatic peak and increased hyaluronidase serum levels suggested replication after intravenous injection in all patients. Increased levels of immune biomarkers (interferon- r,soluble lymphocyte activation ne-3, interleukin (IL)-6, IL-10) were found after VCN-01 administration. Conclusions Treatment with VCN-01 is feasible and has an acceptable safety. Encouraging biological and clinical activity was observed when administered in combination with nab-paditaxel plus gemcitabine to patients with pancreatic adenocarcinoma.
Note: Reproducció del document publicat a:
It is part of: Journal for ImmunoTherapy of Cancer, 2022, vol. 10, num. 3
Related resource:
ISSN: 2051-1426
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
e003255.full.pdf4.35 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons